Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke.
Sign Up to like & getrecommendations! Published in 2022 at "Stroke"
DOI: 10.1161/strokeaha.122.039790
Abstract: It has previously been shown in several animal experiments that platelet GPVI (glycoprotein VI) contributes to thrombosis, particularly in ischemic stroke. Moreover, GPVI levels are upregulated in stroke patients. This review describes the therapeutic roles… read more here.
Keywords: glenzocimab; gpvi glycoprotein; acute ischemic; stroke ... See more keywords